/
PALI
$2.25+$0.34 (+17.99%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$328.4M
174M shares
52-week range
$0.53 – $2.86
74% from low
Sector
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Exchange
NASDAQ
CS
Borrow rate
0.99%
Easy to borrow
Price (6 mo)
Loading chart…
Change$-2945.27
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $260.0K | $15.4K | $0 | $0 | $0 | $250.0K | $0 | $0 |
| Cost of revenue | −$990.0K | $0 | $146.0K | $0 | $0 | $0 | $0 | $0 |
| Gross profit | $1.3M | $15.4K | −$146.0K | $0 | $0 | $250.0K | $0 | $0 |
| Gross margin | 480.8% | 100.0% | — | — | — | 100.0% | — | — |
| R&D | $4.0M | $4.1M | $3.1M | $2.4M | $6.5M | $6.9M | $9.1M | $10.2M |
| Operating income | −$8.3M | −$8.6M | −$9.3M | −$41.9M | −$15.7M | −$13.1M | −$14.9M | −$18.1M |
| EBITDA | −$4.7M | −$8.2M | −$9.9M | −$24.2M | −$14.2M | −$12.3M | −$14.4M | −$16.8M |
| Net income | −$4.9M | −$8.4M | −$10.3M | −$26.6M | −$14.3M | −$12.3M | −$14.4M | −$16.8M |
| Net margin | -1894.2% | -54254.9% | — | — | — | -4920.0% | — | — |
| EPS (diluted) | -18.02 | -35.18 | -186.00 | -2546.10 | -16.53 | -27.01 | -10.19 | -0.30 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $28M | $-0.24 | $-0.31–$-0.20 | 5 |
| 2027 | $48M | $-0.28 | $-0.42–$-0.22 | 5 |
| 2028 | $81M | $-0.36 | $-0.41–$-0.33 | 4 |
| 2029 | $208M | $-0.41 | $-0.41–$-0.41 | 2 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$2.39
Price
$2.25
Implied upside
+6%
Peer comparison
Palisade Bio, Inc. Common Stock
Palisade Bio Inc is a clinical-stage biopharma company focused on identifying and developing therapeutics that protect the integrity of the intestinal barrier. Its portfolio consists of a PALI-2108 for the treatment of IBD, including UC and CD, and is researching PALI-1908.
www.palisadebio.com- Employees
- 14
- IPO / List date
- Apr 28, 2021
- HQ
- CARLSBAD, CA
Held by traders on TradeandTell
No one on the platform currently holds PALI.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 1,454,400 | $2.5M |
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2024-04-08 | 1-for-15reverse |
| 2022-11-16 | 1-for-50reverse |
| 2019-07-18 | 1-for-20reverse |
| 2017-01-09 | 1-for-13reverse |
Recent trades on TradeandTell
No one on the platform has traded PALI yet.
